Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Assets (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Assets for 6 consecutive years, with $523.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets rose 24.88% to $523.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $523.7 million, a 24.88% increase, with the full-year FY2025 number at $523.7 million, up 24.88% from a year prior.
  • Assets was $523.7 million for Q4 2025 at GeneDx Holdings, up from $463.9 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $933.3 million in Q2 2022 to a low of $175.5 million in Q2 2021.
  • A 5-year average of $492.4 million and a median of $476.4 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: soared 431.68% in 2022, then crashed 49.66% in 2023.
  • GeneDx Holdings' Assets stood at $554.1 million in 2021, then fell by 11.4% to $490.9 million in 2022, then decreased by 14.7% to $418.8 million in 2023, then increased by 0.15% to $419.4 million in 2024, then rose by 24.88% to $523.7 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Assets are $523.7 million (Q4 2025), $463.9 million (Q2 2025), and $419.4 million (Q4 2024).